Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.54 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 3/20 | 0.36 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.35 |
| ▸ | DDO | Q99489 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200489 | 0.87 | GABRA1 (0.52) | GABRA1GABRB2DAODDO | |
| SCHEMBL466434 | 0.87 | GABRA1 (0.46) | GABRA1GABRB2LIPGSMN1; SMN2ALDH1A1 | |
| SCHEMBL29574977 | 0.82 | CLCN2 (0.50) | GABRA1GABRB2CLCN2ALDH1A1 | |
| SCHEMBL3789864 | 0.77 | ENPP2 (0.41) | GABRA1GABRB2LIPGPDK2LMNA | |
| SCHEMBL3784531 | 0.76 | GABRA1 (0.45) | GABRA1GABRB2LIPGPDK2DAO | |
| SCHEMBL410387 | 0.75 | LIPG (0.61) | GABRA1GABRB2LIPGLPLMGLL | |
| SCHEMBL29468961 | 0.75 | LIPG (0.61) | GABRA1GABRB2LIPGLPLMGLL | |
| SCHEMBL1762931 | 0.75 | GABRA1 (0.48) | GABRA1GABRB2LIPGLPLDAO | |
| SCHEMBL3785283 | 0.75 | GABRA1 (0.48) | GABRA1GABRB2LIPGLPLDAO | |
| SCHEMBL31075133 | 0.74 | LIPG (0.70) | LIPGLPLMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2025124544-A1 | 3,4-DIHYDRO-2H-BENZO[B][1,4]DIOXEPANE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 华润医药研究院（深圳）有限公司 | 2025-06-19 | — | — | WO | disclosed |
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-109021022-B | Luminescent diazabenzimidazole carbene metal complexes | UDC 爱尔兰有限责任公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20170331054-A1 | LUMINESCENT DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES | UDC IRELAND LTD (IE) | 2017-11-16 | — | — | US | disclosed |
| EP-3239161-A1 | LUMINESCENT DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES | UDC Ireland Limited (IE) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239161-A1 | LUMINESCENT DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES | UDC Ireland Limited (IE) | 2017-11-01 | — | — | EP | disclosed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110416-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110991-A1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1565452-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005007087-A2 | SUBSTITUTED (HETEROCYCLOALKYL)METHYL AZOLE DERIVATIVES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170331054-A1 | LUMINESCENT DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES | OCIAD1, OCIAD2, CACNA1D | GABRA1 258/4885GABRB2 141/4885LIPG 751/4885 |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C3AR1, C5AR1 | GABRA1 1866/4885GABRB2 2591/4885LIPG 3128/4885 |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | GABRA1 919/4885GABRB2 339/4885LIPG 1372/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | GABRA1 1186/4885GABRB2 2657/4885LIPG 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.